Full history for every metric is available with a Kvantra account

Stock profile
Arrowhead Pharmaceuticals, Inc. logo

Arrowhead Pharmaceuticals, Inc. (ARWR)

Country: United States of AmericaSector: HealthcareIndustry: BiotechnologyExchange: NASDAQ
P/E TTM
N/A
History
P/E NTM
N/A
Market cap
5.85B
Currency USD
KvantraRankAbout42
IValue54
IIQuality14
IIIMomentum61
Current price
41.37 USD-5.22%
Close 20 Nov 2026
Interval
Benchmarks

Key financial summary

Financials in USD
2020202120222023202420252026TTM
Total revenue$m881382432414829451451
Operating profit$m-707-707
Net profit$m-85-141-176-205-599-2-724-724
EPS reported$-5.11-5.09
Operating cashflow per share$-1.92-1.92
Capex per share$0.080.08
FCF per share$-2.00-2.00
Free cash flow$m-284-284
Net debt$m-193-193
Book value equity$m50.350.3
Book value per share$0.360.36
Number of sharesm141.63141.63
DPS (TTM paid)$0.000.00

Financial summary

Financials in USD
2020202120222023202420252026TTM
Value
P/E TTMx--
P/B LTMx184.24116.24
P/S LTMx20.5612.97
P/FCF LTMx-32.65-20.60
EV/EBITDA LTMx-16.91-9.37
EV/Sales LTMx22.6412.55
Earnings Yield LTM%-7.81%-11.86%
FCF Yield%-3.06%-4.86%
Quality
ROE%-1439.4%-170.58%
ROIC%-47.58%-47.58%
Operating margin%-156.86%-156.86%
Gross margin%99.60%99.60%
FCF/Sales%-62.98%-62.98%
Growth and momentum
EPS Growth YoY%--
Sales Growth YoY%-45.65%-45.65%
Net Income Growth YoY%--
FCF Growth%--
Operating Profit Growth%--
Dividend and capital structure
Dividend Yield%0.00%0.00%
Dividend Growth%0.00%0.00%
Payout Ratio%--
FCF/Debtx-0.28-0.28
Net Debt/EBITDAx-1.55-1.55
EBIT/Net interestx-7.55-7.55
Net debt/market cap%-2.08%-3.30%
Net debt/Equityx-3.83-3.83
Gross debt/equityx19.8819.88

Price target estimates

Low estimate
High estimate
Price consensus
Last year average price target
Current price41.37 USD
Return Potential

Based on consensus from external analysts. Not Kvantra's opinion.

Ratings

Strong Buy
Buy
Hold
Sell
Strong Sell
Number of covering analysts

Based on consensus from external analysts. Not Kvantra's opinion.

ESG

Metric202420252026
ESG-score
Environmental score
Social score
Governance score
Risk rating

Company overview

Arrowhead Pharmaceuticals, Inc., founded in 1989 and based in Pasadena, California, is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for complex and challenging-to-treat diseases within the United States. The company's extensive therapeutic pipeline primarily leverages RNA interference (RNAi) technology. Among its advanced clinical programs are: ARO-AAT, a Phase II therapeutic targeting liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is undergoing both Phase 2b and Phase 3 clinical evaluations for hypertriglyceridemia; ARO-ANG3, currently in Phase 2b development to reduce the production of angiopoietin-like protein 3; and ARO-HIF2, a Phase 1b candidate designed to treat clear cell renal cell carcinoma. Arrowhead also has several compounds in earlier clinical development, including ARO-HSD in Phase 1/2a for other liver diseases, ARO-ENaC in Phase 1/2a, aimed at decreasing the epithelial sodium channel alpha subunit in lung airways, and ARO-C3, also in Phase 1/2a, for complement-mediated diseases. Further expanding its diverse portfolio, the company is actively developing ARO-Lung2 for chronic obstructive pulmonary disorder (COPD), ARO-DUX4 for facioscapulohumeral muscular dystrophy, ARO-XDH for uncontrolled gout, and ARO-COV for COVID-19 and other pulmonary-borne pathogens. Beyond its core internal programs, Arrowhead is involved in the progression of JNJ-3989, a subcutaneously administered RNAi therapeutic for chronic hepatitis B virus infection; Olpasiran, intended to reduce apolipoprotein A production; and ARO-AMG1, which targets genetically validated cardiovascular pathways. Strategic collaborations are integral to Arrowhead's development efforts. The company holds a licensing and research agreement with Janssen Pharmaceuticals, Inc. for the co-development of ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3, all RNAi therapeutics focused on liver-expressed targets. Additionally, Arrowhead has a licensing and research partnership with Takeda Pharmaceuticals U.S.A., Inc. to develop an RNAi therapeutic candidate specifically for liver disease.

Trades inUSD

Similar companies

For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.

Arrowhead Pharmaceuticals, Inc. (ARWR)

ARWR · NASDAQ · Healthcare
41.37 USD-5.22%
Sign up to track this stock
Benchmarks
KvantraRank42
Market cap5.85B
P/E NTMN/A
P/E TTMN/A
KvantraRank?42 / 100
Value
54
Quality
14
Momentum
61
Financialsin USD
20252026TTM
Analyst target
Consensus
Current41.37 USD
Upside
Price consensus
Last year average price target
Current price41.37 USD
Return Potential

Consensus from external analysts. Not Kvantra's opinion.

Ratings
Strong Buy
Buy
Hold
Sell
Strong Sell

Based on consensus from external analysts. Not Kvantra's opinion.

ESG
202420252026
ESG-score
Environmental score
Social score
Governance score
Risk rating
About

Arrowhead Pharmaceuticals, Inc., founded in 1989 and based in Pasadena, California, is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for complex and challenging-to-treat diseases within the United States. The company's extensive therapeutic pipeline primarily leverages RNA interference (RNAi) technology. Among its advanced clinical programs are: ARO-AAT, a Phase II therapeutic targeting liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is undergoing both Phase 2b and Phase 3 clinical evaluations for hypertriglyceridemia; ARO-ANG3, currently in Phase 2b development to reduce the production of angiopoietin-like protein 3; and ARO-HIF2, a Phase 1b candidate designed to treat clear cell renal cell carcinoma. Arrowhead also has several compounds in earlier clinical development, including ARO-HSD in Phase 1/2a for other liver diseases, ARO-ENaC in Phase 1/2a, aimed at decreasing the epithelial sodium channel alpha subunit in lung airways, and ARO-C3, also in Phase 1/2a, for complement-mediated diseases. Further expanding its diverse portfolio, the company is actively developing ARO-Lung2 for chronic obstructive pulmonary disorder (COPD), ARO-DUX4 for facioscapulohumeral muscular dystrophy, ARO-XDH for uncontrolled gout, and ARO-COV for COVID-19 and other pulmonary-borne pathogens. Beyond its core internal programs, Arrowhead is involved in the progression of JNJ-3989, a subcutaneously administered RNAi therapeutic for chronic hepatitis B virus infection; Olpasiran, intended to reduce apolipoprotein A production; and ARO-AMG1, which targets genetically validated cardiovascular pathways. Strategic collaborations are integral to Arrowhead's development efforts. The company holds a licensing and research agreement with Janssen Pharmaceuticals, Inc. for the co-development of ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3, all RNAi therapeutics focused on liver-expressed targets. Additionally, Arrowhead has a licensing and research partnership with Takeda Pharmaceuticals U.S.A., Inc. to develop an RNAi therapeutic candidate specifically for liver disease.

IndustryBiotechnology
Trades inUSD

For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.

Unlock all fundamental data

Sign up for Free

Unlock all fundamental data

Sign up for Free